Fig. 3: Proportion (%) of in-trial patients achieving sex- and race-specific WC cutoff points for increased metabolic risk according to baseline BMI <35 or ≥35 kg m−2.
From: Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial

WC cutoff points; Asian women <80 cm, non-Asian women <88 cm, Asian men <88 cm, non-Asian men <102 cm.